Sakar Healthcare Limited (NSE:SAKAR) — Market Cap & Net Worth
Market Cap & Net Worth: Sakar Healthcare Limited (SAKAR)
Sakar Healthcare Limited (NSE:SAKAR) has a market capitalization of $210.14 Million (Rs19.43 Billion) as of August 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #16298 globally and #853 in its home market, demonstrating a 6.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sakar Healthcare Limited's stock price Rs885.25 by its total outstanding shares 21949910 (21.95 Million). See capital reinvestment ratio of Sakar Healthcare Limited to understand how much of operating cash flow is reinvested back into capital assets.
Sakar Healthcare Limited Market Cap History: 2017 to 2026
Sakar Healthcare Limited's market capitalization history from 2017 to 2026. Data shows growth from $14.72 Million to $210.14 Million (33.96% CAGR).
Sakar Healthcare Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sakar Healthcare Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Sakar Healthcare Limited's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.69x
Sakar Healthcare Limited's market cap is 0.69 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $14.72 Million | $441.71 Million | $33.78 Million | 0.03x | 0.44x |
| 2018 | $14.12 Million | $530.77 Million | $38.15 Million | 0.03x | 0.37x |
| 2019 | $15.90 Million | $682.49 Million | $70.11 Million | 0.02x | 0.23x |
| 2020 | $23.32 Million | $829.80 Million | $96.23 Million | 0.03x | 0.24x |
| 2021 | $38.61 Million | $947.39 Million | $106.83 Million | 0.04x | 0.36x |
| 2022 | $53.23 Million | $1.28 Billion | $152.43 Million | 0.04x | 0.35x |
| 2023 | $94.96 Million | $1.33 Billion | $127.59 Million | 0.07x | 0.74x |
| 2024 | $70.37 Million | $1.54 Billion | $116.71 Million | 0.05x | 0.60x |
| 2025 | $97.14 Million | $1.78 Billion | $175.02 Million | 0.05x | 0.55x |
| 2026 | $210.14 Million | $2.52 Billion | $304.85 Million | 0.08x | 0.69x |
Competitor Companies of SAKAR by Market Capitalization
Companies near Sakar Healthcare Limited in the global market cap rankings as of August 4, 2026.
Key companies related to Sakar Healthcare Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Sakar Healthcare Limited Historical Marketcap From 2017 to 2026
Between 2017 and today, Sakar Healthcare Limited's market cap moved from $14.72 Million to $ 210.14 Million, with a yearly change of 33.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs210.14 Million | +116.34% |
| 2025 | Rs97.14 Million | +38.03% |
| 2024 | Rs70.37 Million | -25.90% |
| 2023 | Rs94.96 Million | +78.39% |
| 2022 | Rs53.23 Million | +37.87% |
| 2021 | Rs38.61 Million | +65.55% |
| 2020 | Rs23.32 Million | +46.64% |
| 2019 | Rs15.90 Million | +12.61% |
| 2018 | Rs14.12 Million | -4.03% |
| 2017 | Rs14.72 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Sakar Healthcare Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $210.14 Million USD |
| MoneyControl | $210.14 Million USD |
| MarketWatch | $210.14 Million USD |
| marketcap.company | $210.14 Million USD |
| Reuters | $210.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more